Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Octapharma turns human blood plasma and lab-grown human cells into medicines for people with serious immune, bleeding, and other disorders, selling them in about 120 countries.
Octapharma is a Swiss company that makes medicines out of human blood plasma โ the yellowish liquid left after red cells are removed โ and out of proteins produced by human cells grown in a lab. Its customers are hospitals, clinics, and doctors who use these treatments on patients with rare and serious conditions: people whose immune systems attack their own nerves, hemophiliacs whose blood won't clot, burn victims, and patients needing intensive care. The company is privately held, founded in 1983 and still family-controlled, based in Lachen, Switzerland.
The core business is a strange kind of manufacturing. Plasma is collected from thousands of donors, then shipped to big plants where it is thawed, filtered, and pulled apart into its individual proteins โ albumin, immunoglobulins, clotting factors โ each of which becomes a separate medicine. The hard part is not the science alone but the sheer scale and safety: every batch must be screened for viruses, and regulators in each country must approve each product. That is why the industry is dominated by a handful of big players, and why Octapharma has spent heavily on new plants and therapies to stay near the front. Its main competitors are global plasma giants like CSL (Australia), Grifols (Spain), and Takeda (Japan), all of which run similar collection-and-fractionation networks. Octapharma's edge is partly its long history in niche proteins and its willingness to invest in new production capacity โ it opened a large plasma-fractionation plant in the United States and has been expanding its immunoglobulin and rare-disease portfolio. Because the company is private, its financials are not fully public, but it is widely reported as one of the world's largest plasma-product makers. Watch the money flow: plasma collection is expensive, and a single new plant can cost hundreds of millions. Octapharma's strategy is to keep building capacity and adding higher-value therapies, so it can sell more of the expensive proteins rather than the cheaper bulk products. The risk is that plasma supply is hard to scale and heavily regulated, and competitors are doing the same thing. For a private, family-run firm, that means the real test is whether its plants run efficiently and its new products win approvals โ not whether it pays a dividend.
The company also illustrates a quiet but vital corner of medicine: many of the drugs that keep rare-disease patients alive are not invented in a lab from scratch but extracted from donated human blood. Octapharma sits in the middle of that chain, buying plasma, splitting it into proteins, and selling the results to health systems that have few alternatives.
Saved answer ยท last researched 15 Nov 2026